Riluzol

General characteristics. Structure:

Active agent: 50 mg of a riluzol.

Pharmacological properties:

Riluzol is derivative petrolthiazol, inhibiting release of a glutamate (the main exciting neurotransmitter in TsNS) on presynaptic membranes of nerve terminations, and is probably an antagonist of exciting amino acids on postsynaptic membranes of nerve terminations. It leads to decrease in concentration of a glutamate on synapses, and these actions probably interfere with damage of motor neurons and development of a side amyotrophic sclerosis. This disease is characterized by a progressive degeneration of pyramidal nerve pathways or motor neurons, shown by a muscular atrophy and paresis. Riluzol for several months slows down development of heavy symptoms in patients with a side amyotrophic sclerosis.

Indications to use:

Increase in life expectancy or the period without the need for mechanical ventilation at patients with the side amyotrophic sclerosis (SAS).

Route of administration and doses:

The recommended daily dose for adult patients, including for elderly people — 100 mg (on 50 mg each 12 hours). Owing to lack of data on safety use of a riluzol for children and patients with disturbance of renal functions is not recommended.

Features of use:

In the first three months of therapy it is recommended to control monthly the ALAT levels, further each 3 months until the end of the first year of therapy. In the further period it is recommended to carry out regular control. At patients, treated riluzoly, cases of development of an intersticial disease of lungs and a neutropenia were known. At dizzinesses and/or вертиго patients are not recommended to manage vehicles or to work with mechanisms.

Side effects:

Most often adynamy (weakness of a body), nausea, increase in values of hepatic tests. Also headaches, dizziness, paresthesia around a mouth, drowsiness, tachycardia, a diarrhea, abdominal pains, vomiting.

Interaction with other medicines:

Ftorkhinolona (norfloxacin, ciprofloxacin, пефлоксацин) increase the level of a rinuzol in a blood plasma and its hepatotoxic. A hepatotoxic of a riluzol is also increased by other hepatotoxic drugs. Rifampicin reduces the plasmatic level of a riluzol and its action.

Contraindications:

Hypersensitivity to active ingredient, liver diseases, or reference values of hepatic tests more than by 3 times exceed value of an upper limit of norm, pregnancy and feeding by a breast.

Overdose:

There are no data on overdose.

Storage conditions:

At a temperature up to 25 °C.

Issue conditions:

According to the recipe

Packaging:

10, 30, 50, 56, 60, 90, 100 tablets, coated.